Intrexon Corporation (XON) Shares are Down -1.53%

Intrexon Corporation (XON) has risen sharply, recording gains of 15.15% in the past 4 weeks. However, the stock has corrected -1.53% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 13.98% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 8.82% and the 50-Day Moving Average is 9.41%. Intrexon Corporation (NYSE:XON): On Fridays trading session , Opening price of the stock was $28.63 with an intraday high of $28.63. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $27.65. However, the stock managed to close at $28.27, a loss of 1.43% for the day. On the previous day, the stock had closed at $28.68. The total traded volume of the day was 1,143,102 shares.


The company Insiders own 59.6% of Intrexon Corporation shares according to the proxy statements. Institutional Investors own 84.59% of Intrexon Corporation shares. Also, JMP Securities initiates coverage on Intrexon Corporation (NYSE:XON). The current rating of the shares is Market Outperform, according to the research report released by the firm. The rating by the firm was issued on May 3, 2016.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.